Merck shares tumble on Q4 earnings miss, weak 2025 guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/28/2026
- Wall St to open lower as oil spikes after Trump rejects Iran peace proposal
- S&P 500 breadth hits lowest level since dot-com bubble, Goldman says
- Nvidia’s AI dominance funds historic $150 billion buyback
- MongoDB stock drops 15% as CEO Desai resigns for Meta
- Jefferies cuts Roblox to Underperform, says rally is too optimistic
- Exclusive-Activist Jana pushes Fiserv to accelerate cost cuts and tap Palantir
- Oppenheimer sees AI software winners as focus shifts to ROI
- Nvidia releases AI safety software it says could have stopped Hugging Face hack
- S&P 500 breadth hits lowest level since dot-com bubble, Goldman says
- Cantor Fitzgerald Starts Lexicon Pharmaceuticals (LXRX) at Overweight
Merck (MRK) PT Lowered to $129 at Goldman Sachs
February 5, 2025 6:35 AM ESTGoldman Sachs analyst Chris Shibutani lowered the price target on Merck (NYSE: MRK) to $129.00 (from $135.00) while maintaining a Buy rating.
The analyst comments "Amidst a backdrop where MRK delivered strong operational performance across the majority of the company's key franchises, the announcement of 2025 guidance, highlighted by the negative impact of the nettlesome dynamics for... More
